Prosecution Insights
Last updated: November 04, 2026
Application No. 18/174,451

SYSTEMS, METHODS, AND DEVICES FOR ALLEVIATING ERECTILE DYSFUNCTION AND OTHER CONDITIONS USING AN ERECTILE DYSFUNCTION DEVICE

Final Rejection §102
Filed
Feb 24, 2023
Priority
Aug 26, 2020 — provisional 63/070,724 +2 more
Examiner
COX, THADDEUS B
Art Unit
3791
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Giddy Holdings Inc.
OA Round
2 (Final)
77%
Grant Probability
Favorable
3-4
OA Rounds
0m
Est. Remaining
96%
With Interview

Examiner Intelligence

Grants 77% — above average
77%
Career Allowance Rate
914 granted / 1186 resolved
+7.1% vs TC avg
Strong +19% interview lift
Without
With
+18.8%
Interview Lift
resolved cases with interview
Typical timeline
2y 9m
Avg Prosecution
49 currently pending
Career history
1238
Total Applications
across all art units

Statute-Specific Performance

§101
6.6%
-33.4% vs TC avg
§103
32.4%
-7.6% vs TC avg
§102
21.2%
-18.8% vs TC avg
§112
32.7%
-7.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1186 resolved cases

Office Action

§102
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . This Office Action is responsive to the Amendment filed 30 September 2026. Claims 1 and 2 are currently under consideration. The Office acknowledges the amendments to claim 1. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 1-2 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Fischer (U.S. No. 5,439,007). Regarding claim 1, Fischer discloses a method of treating an ailment in a patient (Abstract), the method comprising: a. wearing a penile constriction device 12 to promote sexual intercourse, masturbation, or both; b. maintaining an erection; and c. engaging in sexual intercourse, masturbation, or both with the worn penile constriction device, wherein engaging in sexual intercourse, masturbation, or both with the worn penile constriction device results in ejaculation and/or orgasm that treats the ailment by releasing endorphins, oxytocin, serotonin, and dopamine, and reducing cortisol levels, (Figs. 3-6; col. 1, lines 50-52; col. 3, lines 30-54; col. 4, lines 39-56; col. 6, lines 14-18; col. 6, lines 45-54). While Fischer does not specifically teach releasing endorphins, oxytocin, serotonin, and dopamine, nor reducing cortisol levels, the present application teaches that orgasms release endorphins, oxytocin, serotonin, and dopamine, as well as reduce cortisol levels ([0357]-[0375]). Accordingly, as the method taught by Fischer results in ejaculation/orgasm, it also releases endorphins, oxytocin, serotonin, and dopamine, and reduces cortisol levels. Regarding claim 2, Fischer discloses that the ailment comprises anxiety, depression, post-traumatic stress disorder, low self-esteem, seasonal affective disorder (SAD), low testosterone, stress, ED, prostate cancer, hypertension, coronary artery disease, diabetes, heart disease, high blood pressure, low blood pressure, coronary artery disease (CAD), COPD, hypertension, headache, migraines, obesity, or any combination thereof (col. 1, lines 6-41). Response to Arguments Applicant’s arguments with respect to the rejections under 35 U.S.C. 112(b) have been fully considered and are persuasive in light of the amendments. The rejections have been withdrawn. Applicant's arguments with respect to the rejections under 35 U.S.C. 102 have been fully considered but they are not persuasive. Applicant argues that Fischer does not use any of the terms “endorphins,” “oxytocin,” “serotonin,” “dopamine,” or “cortisol,” and therefore fails to teach the recited method. However, as detailed supra, the examiner disagrees. Again, the present application teaches that the act of having an orgasm results in the release of endorphins, oxytocin, serotonin, and dopamine, along with the reduction of cortisol. Thus, as Fischer’s method results in ejaculation/orgasm, it necessarily releases endorphins, oxytocin, serotonin, and dopamine, while reducing cortisol levels. In other words, Fischer’s method would achieve the intended result that is recited by the claims. The present application does not teach or recite anything additional, beyond having an orgasm, that releases such hormones/chemicals/endorphins. There is no step in the present application that achieves these results that is not taught by Fischer. This is also not something that was discovered in the present application, as it is known that having orgasms releases endorphins, oxytocin, serotonin, and dopamine, while reducing cortisol levels (see, e.g., https://www.essence.com/lifestyle/orgasms-for-better-looking-skin/ and https://nypost.com/2017/12/12/my-doctor-prescribed-me-orgasms-to-treat-my-depression/). Conclusion THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to THADDEUS B COX whose telephone number is (571)270-5132. The examiner can normally be reached M-F 9am-6pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jason M. Sims can be reached at (571)272-7540. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /THADDEUS B COX/Primary Examiner, Art Unit 3791
Read full office action

Prosecution Timeline

Feb 24, 2023
Application Filed
Apr 01, 2026
Non-Final Rejection mailed — §102
Sep 30, 2026
Response Filed
Oct 21, 2026
Final Rejection mailed — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12773570
EEG BASED MULTI-FREQUENCY STIMULATION
3y 3m to grant Granted Oct 27, 2026
Patent 12773160
TUMESCENSE MONITORING SYSTEM FOR DIAGNOSING ERECTILE DYSFUNCTION AND METHODS OF USE
3y 7m to grant Granted Oct 27, 2026
Patent 12773519
SYSTEM AND METHOD FOR SOOTHING INFANTS
3y 3m to grant Granted Oct 27, 2026
Patent 12766070
PARTNER TOY FOR MASSAGING A FIRST AND A SECOND PERSON
4y 5m to grant Granted Oct 20, 2026
Patent 12766288
METHODS AND SYSTEMS OF PAVLOVIAN SLEEP INDUCTION
4y 4m to grant Granted Oct 20, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
77%
Grant Probability
96%
With Interview (+18.8%)
2y 9m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 1186 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month